As previously reported, Raymond James analyst Danielle Brill upgraded Disc Medicine (IRON) to Strong Buy from Outperform with a price target of ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

which are in late stage development for acute hepatic porphyrias and hypercholesteroaemia respectively. He said: “With the potential for the sequential launches of several new medicines in the ...

Third-generation oral contraceptives are an association of low-dose ethinyl estradiol and potent testosterone-derived progestins, developed in order to improve general and vascular tolerance. They ...

Since Carl Djerassi and Gregory Pincus brought the proof of concept of OCs in the early 1960s, with a pill containing norethidronel as a progestin and mestranol as an estrogen, many different ...

CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized treat ...